The Effects of Oxytocin on Social Touch

NCT ID: NCT03278860

Last Updated: 2018-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-28

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to investigate whether intranasal oxytocin (24IU) can enhance hedonic experience and associated brain-reward reward responses to social touch.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A double-blind, within-subject, placebo controlled design is employed in this study. In total 50 healthy male subjects will be recruited and they will come twice, once with the administration of oxytocin nasal spray and the other placebo (interval time is more than 2 weeks). 45 minutes after treatment subjects will be applied two different types of pleasant touch: social touch from a masseur (professional therapist) and non-social touch from a massage device. After each condition the subjects will be asked to rate pleasantness, likability, and arousal. Simultaneously functional brain activity will be acquired via fMRI. Blood samples will be taken before and after the intervention to assess oxytocin levels. All subjects were asked to complete a range of questionnaires measuring trait personality and mood: Beck Depression Inventory (BDI), Cheek and Buss Shyness Scale (CBSS),Autism Spectrum Quotient (ASQ), Empathy Quotient (EQ), NEO Five Factor Inventory (NEO-FFI), Liebowitz Social Anxiety Scale (LSAS),Behavioral Inhibition System and Behavioral Activation System Scale (BISBAS),Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ),State-Trait Anxiety Inventory (STAI), Social Touch Questionnaire (STQ), Sensory over Responsivity Scale (SOR) and Under Responsivity Scale (URS) one day before the first scanning. On the first and second scanning day, the subjects were asked to complete Positive and Negative Affect Schedule (PANAS) before and after treatment administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized placebo-controlled double-blind within-subject design
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxytocin then placebo

Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).

Group Type EXPERIMENTAL

intranasal oxytocin

Intervention Type DRUG

24 IU of oxytocin nasal spray will be applied to each subject.

intranasal placebo

Intervention Type DRUG

an identical amount of placebo nasal spray will be applied to each subject.

Placebo then oxytocin

Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).

Group Type EXPERIMENTAL

intranasal oxytocin

Intervention Type DRUG

24 IU of oxytocin nasal spray will be applied to each subject.

intranasal placebo

Intervention Type DRUG

an identical amount of placebo nasal spray will be applied to each subject.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intranasal oxytocin

24 IU of oxytocin nasal spray will be applied to each subject.

Intervention Type DRUG

intranasal placebo

an identical amount of placebo nasal spray will be applied to each subject.

Intervention Type DRUG

intranasal oxytocin

24 IU of oxytocin nasal spray will be applied to each subject.

Intervention Type DRUG

intranasal placebo

an identical amount of placebo nasal spray will be applied to each subject.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects without any past or present psychiatric or neurological disorders

Exclusion Criteria

* History of brain injury
* Medical or mental illness
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Electronic Science and Technology of China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Keith Kendrick

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Qin Li, MA

Role: STUDY_CHAIR

University of Electronic Science and Technology of China

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Keith M Kendrick, Dr.

Role: CONTACT

86-28-61830811

Benjamin Becker, Dr.

Role: CONTACT

86-28-61830988

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Qin Li, MA

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Chen Y, Li Q, Zhang Q, Kou J, Zhang Y, Cui H, Wernicke J, Montag C, Becker B, Kendrick KM, Yao S. The Effects of Intranasal Oxytocin on Neural and Behavioral Responses to Social Touch in the Form of Massage. Front Neurosci. 2020 Dec 4;14:589878. doi: 10.3389/fnins.2020.589878. eCollection 2020.

Reference Type DERIVED
PMID: 33343285 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UESTC-neuSCAN-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oxytocin, Emotions and Mirror Neurons
NCT02228031 COMPLETED EARLY_PHASE1
Touch and Attention MRI Study
NCT01432288 COMPLETED
Vasopressin and the Social Brain
NCT02394054 COMPLETED EARLY_PHASE1
fMRI Tracking taVNS in ASD
NCT06698328 COMPLETED NA